000 01427 a2200385 4500
005 20250518053926.0
008 ####s 0 0 eng d
022 _a1569-8041
024 7 _a10.1093/annonc/mdz219
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKulke, M H
245 0 0 _aA randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
_h[electronic resource]
260 _bAnnals of oncology : official journal of the European Society for Medical Oncology
_c11 2019
300 _a1846 p.
_bdigital
500 _aPublication Type: Journal Article; Published Erratum
700 1 _aRuszniewski, P
700 1 _aVan Cutsem, E
700 1 _aLombard-Bohas, C
700 1 _aValle, J W
700 1 _aDe Herder, W W
700 1 _aPavel, M
700 1 _aDegtyarev, E
700 1 _aBrase, J C
700 1 _aBubuteishvili-Pacaud, L
700 1 _aVoi, M
700 1 _aSalazar, R
700 1 _aBorbath, I
700 1 _aFazio, N
700 1 _aSmith, D
700 1 _aCapdevila, J
700 1 _aRiechelmann, R P
700 1 _aYao, J C
773 0 _tAnnals of oncology : official journal of the European Society for Medical Oncology
_gvol. 30
_gno. 11
_gp. 1846
856 4 0 _uhttps://doi.org/10.1093/annonc/mdz219
_zAvailable from publisher's website
999 _c30000049
_d30000049